SCHEMBL257698

SCHEMBL257698

COc1ccc(-c2c(C)nn3c(-c4ccccc4)cc(Cl)nc23)cc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.78
MAPK1 P28482 3/20 0.78
TP53 P04637 1/20 0.62
TDP1 Q9NUW8 2/20 0.54
NPC1 O15118 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CYP1A2 P05177 1/20 0.52
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
STAT1 P42224 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
CRHR1 P34998 1/20 0.48
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257389 0.92 MAPT (0.65) MAPTMAPK1TP53NPC1NPSR1
SCHEMBL15042157 0.88 TP53 (0.67) MAPTMAPK1TP53TDP1NPC1
SCHEMBL15020632 0.88 TP53 (0.79) MAPTMAPK1TP53TDP1NPC1
SCHEMBL257514 0.87 MAPT (0.60) MAPTMAPK1TP53TDP1NPC1
SCHEMBL257404 0.85 MAPT (0.59) MAPTMAPK1TP53TDP1NPSR1
SCHEMBL257327 0.85 MAPT (0.58) MAPTMAPK1TP53TDP1CYP1A2
SCHEMBL15121510 0.81 MAPT (0.63) MAPTMAPK1TP53TDP1NPC1
SCHEMBL257542 0.78 TP53 (0.55) MAPTMAPK1TP53TDP1NPC1
SCHEMBL256922 0.78 TP53 (0.65) MAPTMAPK1TP53TDP1NPC1
SCHEMBL13517062 0.78 MAPT (0.65) MAPTMAPK1TP53TDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885MAPK1 519/4885TP53 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.